DMAC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
10.5M
+0.2%
10.5M
+13.8%
9.2M
+2.0%
9.0M
+12.8%
8.0M
R&D
8.2M
+2.1%
8.0M
+19.2%
6.7M
+4.1%
6.4M
+10.6%
5.8M
SG&A
2.3M
-6.0%
2.5M
-0.8%
2.5M
-3.2%
2.6M
+18.8%
2.2M
Operating Income
-10498000
-0.2%
-10482000
-13.8%
-9213000
-2.0%
-9033000
-12.8%
-8007000
EBITDA
-10486000
-0.1%
-10471000
-13.8%
-9202000
-2.1%
-9015000
-12.6%
-8004000
Net Income
-10139000
-1.0%
-10042000
-14.9%
-8740000
-1.4%
-8620000
-12.0%
-7699000
EPS (Basic)
$-0.19
+0.0%
$-0.19
-11.8%
$-0.17
+0.0%
$-0.17
+5.6%
$-0.18
EPS (Diluted)
$-0.19
+0.0%
$-0.19
-11.8%
$-0.17
+0.0%
$-0.17
+5.6%
$-0.18
Shares (Diluted)
53.9M
+0.2%
53.8M
+2.5%
52.5M
+5.8%
49.6M
+15.5%
43.0M
DiaMedica Therapeutics (DMAC) โ€” Financials